Clinical Trial Update: Study of Intrathecal Administration of Onasemnogene Abeparvovec-xioi for Spinal Muscular Atrophy [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating intrathecal administration of onasemnogene abeparvovec-xioi for spinal muscular atrophy was terminated, with results posted on…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Zolgensma (onasemnogene abeparvovec)

Snippet

Sponsor: Novartis Gene Therapies | Conditions: Spinal Muscular Atrophy | Phase 1 | Status: TERMINATED | Results posted: 2023-02-16